Bodybuilding peptide vial
Why it’s worth combining IGF-1 and Growth Hormone
The first argument that Janssen comes up with is that IGF-1 remains active for longer in the body if you inject it in combination with growth hormone. This is because IGF-1 is active for longer if it is attached to the binding protein IGFBP3.
If you inject IGF-1 on its own, the production of this binding protein goes down. But if you inject growth hormone and IGF-1 together, the concentration of this binding protein increases. That might mean that you would have to inject less frequently, as IGF-1 breaks down quickly in the body.
A second argument is that growth hormone makes the cells ‘ignore’ insulin. As a result, blood sugar levels rise, as does the insulin level. In the long run this might not be so beneficial to health, and it would inhibit muscle growth. If you use IGF-1 together with growth hormone, then the muscle cells become more sensitive to insulin. And that would mean more muscle protein build-up.
The advantage of combining IGF-1 and GH
is also a potential disadvantage, according to Janssen. On a molecular level the same processes involved in muscle growth are also found in cancer cells and tumors. The combination of both hormones might therefore give any tumors a growth stimulus. The same applies to other side effects such as undesirable growth of the jawbone, headache and trapped nerves in the hands.
In the final section of the article, the endocrinologist stresses that there have been very few studies on the effect of combined administration of GH and IGF-1, and that his article is mainly theoretical. “Determination of whether co-administration of GH and IGF-I is indeed superior to GH alone or IGF-I alone awaits further study”, concludes Janssen.
CJC-1295 has shown to increase gh and IGF levels
To identify biomarkers of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) action in human serum.
The search for new markers of GH activity has received extensive attention given that the current biomarkers (IGF-1, IGFBP-3 and collagen peptides) show substantial variability in the population, and are not reliably predictive of either the physiologic effects of GH therapy or the detection of GH abuse by athletes. GH releasing hormone (GHRH) is a polypeptide synthesized in the hypothalamus that binds to receptors on pituitary somatotropes to promote the synthesis and release of GH. Serum GH and IGF-1 levels have been shown to increase with administration of GHRH or CJC-1295, a long-acting GHRH analog.
Sera from 11 healthy young adult men before and one week after CJC-1295 injection were analyzed by two-dimensional gel electrophoresis for proteomic changes. Serum proteins displaying significant changes before and after treatment were subsequently identified using mass spectrometry. In addition, correlations between these proteins and GH or IGF-1 levels were evaluated.
Two protein spots that displayed decreased intensities after treatment were identified as an apolipoprotein A1 isoform and a transthyretin isoform. Three protein spots upregulated by CJC-1295 treatment included beta-hemoglobin, a C-terminal fragment of albumin, and a mix of an immunoglobulin fragment and another C-terminal albumin fragment. A linear relationship was found between the spot containing immunoglobulin and albumin fragments and IGF-1 levels.
Although the molecular mechanisms linking the identified proteins to GH and IGF-1 biological activity remain to be clarified, the results suggest that they represent potential biomarkers of GH and/or IGF-1 action.
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ.